All In Biotech

Drug Trial Radar · NCT04736706

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,688 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,688

Actual

Start

Apr 14, 2021

Primary completion

Feb 4, 2026

Study completion Apr 22, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Eisai Inc.
First posted
Feb 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • PembrolizumabBiological

    Pembrolizumab 400 mg administered Q6W via IV infusion

  • BelzutifanDrug

    Belzutifan 120 mg administered QD via oral tablet

  • Pembrolizumab/QuavonlimabBiological

    Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion

  • LenvatinibDrug

    Lenvatinib 20 mg administered QD via oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 57 months
  2. Overall Survival (OS)Time frame: Up to approximately 57 months

Locations

262 sites in 35 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham ( Site 0010)

    Birmingham, Alabama

  • UC San Diego ( Site 0050)

    La Jolla, California

  • Cedars Sinai Medical Center ( Site 0027)

    Los Angeles, California

  • University of California Irvine ( Site 0029)

    Orange, California

  • UCLA Hematology Oncology Santa Monica ( Site 0048)

    Santa Monica, California

  • Hartford Hospital ( Site 0024)

    Hartford, Connecticut

  • Advent Health Hematology & Oncology ( Site 0003)

    Orlando, Florida

  • University Cancer & Blood Center, LLC ( Site 0057)

    Athens, Georgia

  • Emory University Winship Cancer Institute ( Site 0012)

    Atlanta, Georgia

  • Rush University Medical Center ( Site 0040)

    Chicago, Illinois

  • Parkview Cancer Institute ( Site 0088)

    Fort Wayne, Indiana

  • Norton Cancer Institute - St. Matthews ( Site 0065)

    Louisville, Kentucky

  • Ochsner Medical Center ( Site 0049)

    New Orleans, Louisiana

  • New England Cancer Specialists ( Site 0082)

    Scarborough, Maine

  • Massachusetts General Hospital ( Site 0094)

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center ( Site 0089)

    Boston, Massachusetts

  • Dana Farber Cancer Institute ( Site 0093)

    Boston, Massachusetts

  • Lahey Hospital & Medical Center ( Site 0090)

    Burlington, Massachusetts

  • Henry Ford Hospital ( Site 0038)

    Detroit, Michigan

  • Cancer & Hematology Centers of Western Michigan ( Site 0018)

    Grand Rapids, Michigan

  • HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)

    Saint Louis Park, Minnesota

  • Regions Hospital ( Site 0095)

    Saint Paul, Minnesota

  • University of Mississippi Medical Center ( Site 0037)

    Jackson, Mississippi

  • Dartmouth Hitchcock Medical Center ( Site 0075)

    Lebanon, New Hampshire

  • Roswell Park Cancer Institute ( Site 0032)

    Buffalo, New York

  • R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)

    Lake Success, New York

  • Sidney Kimmel Center for Prostate and Urologic Cancers ( Site 0055)

    New York, New York

  • Oregon Health & Science University ( Site 0071)

    Portland, Oregon

  • Ralph H. Johnson VA Center ( Site 0073)

    Charleston, South Carolina

  • University of Tennessee Medical Center Knoxville ( Site 0019)

    Knoxville, Tennessee

  • Vanderbilt University Medical Center ( Site 0069)

    Nashville, Tennessee

  • UTSW Medical Center ( Site 0015)

    Dallas, Texas

  • Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)

    Wenatchee, Washington

  • Liverpool Hospital ( Site 4006)

    Liverpool, New South Wales, Australia

  • Macquarie University ( Site 4007)

    Macquarie University, New South Wales, Australia

  • Lyell McEwin Hospital ( Site 4004)

    Elizabeth Vale, South Australia, Australia

  • Monash Health ( Site 4008)

    Clayton, Victoria, Australia

  • Fiona Stanley Hospital ( Site 4009)

    Murdock, Western Australia, Australia

  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0302)

    São Paulo, Brazil

  • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0300)

    São Paulo, Brazil

Showing 40 of 262 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.